AMGEN

Their core work

Amgen is a global biopharmaceutical company that brings industry-scale drug development expertise to EU collaborative research. Within H2020, their Belgian entity contributes to projects spanning oncology, hematology, digital health, and regulatory science. They provide real-world clinical data, biomarker expertise, and pharmaceutical R&D perspectives to large public-private partnerships, particularly within the IMI (Innovative Medicines Initiative) ecosystem. Their participation bridges the gap between academic research findings and the practical realities of drug approval, reimbursement, and patient access.

What they specialise in

How they've shifted over time

Amgen's early H2020 involvement (2015–2018) centered on regulatory and market access innovation — adaptive trial designs, HTA strategies, and multi-party collaboration models for faster drug approval (ADAPT-SMART). Their portfolio then expanded into disease-specific big data platforms for oncology and hematology (HARMONY, ITCC-P4, DO-IT). By 2019–2024, their focus shifted decisively toward digital endpoints, AI-driven treatment optimization, and real-world evidence — reflecting the broader pharma industry's move from traditional clinical trials toward data-driven, digitally-enabled drug development.

Amgen is moving toward AI-powered clinical decision support and digital biomarkers, making them a strong partner for projects combining pharma expertise with health data science.

How they like to work

Amgen exclusively participates as a consortium partner, never as coordinator — consistent with large pharma's role in IMI-type public-private partnerships where academic or SME partners typically lead. With 174 unique partners across 22 countries in just 6 projects, they operate in very large consortia (averaging ~30 partners per project). This hub-style network means they bring extensive cross-European connections but expect well-structured governance in any consortium they join.

With 174 unique consortium partners spread across 22 countries, Amgen has one of the broadest collaborative networks relative to their project count — a direct result of participating in large IMI-scale partnerships. Their reach is pan-European with strong connections to academic medical centers, regulatory bodies, and other pharmaceutical companies.

What sets them apart

Amgen brings the perspective of a top-10 global biopharmaceutical company to EU research consortia — few partners can match their depth in drug development, regulatory strategy, and commercial market access. Their Belgian hub provides direct access to EU regulatory and policy environments. For consortium builders, Amgen offers credibility with regulators and payers, real-world clinical datasets, and the ability to translate research outputs toward actual therapeutic products.

Highlights from their portfolio

• OPTIMA
  Their most recent project (2021–2026) combines AI with real-world evidence to optimize solid tumor treatment across Europe — represents their current strategic direction.
• HARMONY
  A flagship IMI big-data platform for hematological malignancies running until 2023, aggregating patient data across Europe at unprecedented scale.
• MOBILISE-D
  Bridges digital mobility assessment with regulatory endorsement — an unusual intersection of digital health technology and pharmaceutical regulatory science.